Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (373)
NICE advice (1)
Quality standard (8)
Guidance programme
Guidance programme
Clinical guidelines (25)
Diagnostics guidance (6)
Health technology evaluations (14)
Highly specialised technologies guidance (5)
Interventional procedures guidance (15)
Medical technologies guidance (8)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (300)
Apply filters
Showing 311 to 320 of 373
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Technology appraisal guidance
TBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]
Technology appraisal guidance
TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Surgical vessel sealing systems (MT798)
Medical technologies guidance
TBC
Suspected Cancer: recognition and referral (update)
NICE guideline
13 March 2026
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
19 November 2025
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
TBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]
Technology appraisal guidance
10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413
Technology appraisal guidance
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Previous page
1
…
30
31
Current page
32
33
34
…
38
Page
32
of
38
Next page
Results per page
10
25
50
All
Back to top